Mutant SETBP1 enhanced the activity of the MYC pathway to facilitate CSF3R-related myeloproliferative neoplasms [15], and the NRAS-driven MAPK signal was activated by mutated SETBP1 to accelerate aggressive leukemia [16]. This evidence concerns the gene SETBP1 and myeloproliferative disorder.